Honored to Join the Advisory Board of CancerNetwork - Yan Leyfman @yleyfman.bsky.social oncodaily.com/career/advis... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerNetwork

I’m deeply honored to join the Advisory Board of ONCOLOGY / CancerNetwork. 🎉 Thank you to Ariana Pelosci & the editorial team for this invitation — I’m grateful for the opportunity to work alongside such an esteemed group of clinical and scientific leaders. 🙏

Grateful to the Humanity Rx Podcast for highlighting my story, my passion for oncology & my commitment to advancing patient care & research innovation. As one of the few remaining survivors of the after-effects of Chernobyl, my own complex medical journey as a child shaped my path toward medicine.

Yan Leyfman: FDA Accepts Bristol Myers Squibb’s Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL @yleyfman.bsky.social @bristolmyerssquibb.bsky.social oncodaily.com/voices/yan-l... #Cancer #Oncology #OncoDaily #Health #Medicine

🎥 MedNews Week x OncLive x Women in Lymphoma Present: 🌟 Voices in Lymphoma: Women Shaping Care 🌟 Career Development & Mentorship in Medicine 🗓️ Tuesday, August 12 ⏰ 6:30 PM EST

🧪 Real-world study supports talquetamab as a viable bridging strategy to BCMA CAR-T in RRMM 🔄 📌 Key Takeaways: Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.

🧬✨ Hope Through Mitochondrial Donation A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births.

🎥 MedNews Week x OncLive x Women in Lymphoma Present: 🌟 Voices in Lymphoma: Women Shaping Care 🌟 💡 Follicular Lymphoma: General Concept and First Line Strategies 🗓️ Tuesday, July 15 ⏰ 6:30 PM EST

AI’s Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma - Yan Leyfman @yleyfman.bsky.social oncodaily.com/insight/yan-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #NPC #NasopharyngealCarcinoma

A breakthrough for blood cancer detection? In a Nature Medicine study—published just days after their labs were damaged in an Iranian missile attack—Shlush, Tanay, Furer, Milman & Rappoport reveal a potential game-changer:

🚨 Latest in Type 2 Diabetes & Weight Management 🚨 New data from the phase 3 ACHIEVE-1 trial shows promising results for Orforglipron, a once-daily, oral, nonpeptide GLP-1 receptor agonist.

🚨 Historic FDA Approval Alert! 🚨 The FDA has just approved Yeztugo (lenacapavir) — a game-changing HIV prevention drug that offers **near-complete protection with just 1 injection every 6 months. 💉🛡️ www.statnews.com/2025/06/18/f...

🔬 AI Meets Hematopathology 🧬 Bone marrow slide interpretation is complex, time-consuming, and prone to error. A new deep learning model, DeepHeme, changes the game.

Great presentation about the efficacy of Bispecific Chimeric T Cell Receptors for cancer therapy at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Stanley Riddell of FRED HUTCHINSON CANCER RESEARCH

Great presentation about the promise of armored CAR T cells without lymphodepletion therapy at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Renier Brentjens of Roswell Park Comprehensive Cancer Center.

🚨 New Study Alert: CAR-T Prep Reimagined! Can bendamustine replace Flu/Cy as lymphodepleting chemo before CAR-T in relapsed/refractory #NHL? 🧪 In a large real-world study (n=265), bendamustine showed:

Great Gene Editing Keynote highlighting the promise & potential of CAR-M at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Saar Gill of University of Pennsylvania.

Great Keynote address highlighting the history of PD-1/PD-L1 inhibitors at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Dr. Antoni Ribas of UCLA. #nyas #cancerimmunotherapy #io #cancerimmunotherapy25 #cancerimmunotherapy2025

Tomorrow @ 6:30pm EST MedNewsWeek x OncLive x WiL Present: Voices in Lymphoma: Women Shaping Care A powerful conversation on evolving paradigms in first relapse DLBCL with two trailblazing experts Dr Manali Kamdar & Dr Sonali Smith bsky.app/profile/yley...

🚨 MedNews Week KEYNOTE Conference 🚨 We’re honored to welcome Dr. Markus Mapara, world-renowned leader in transplantation and cell therapy, as our next MedNews Week x OncLive Keynote Speaker! 🧬 🎥 : www.onclive.com/view/allogen...

🧬 Breakthrough in Organoid Vascularization! A major step forward in modeling human development 🔬 Stanford reseachers have successfully created vascularized cardiac and hepatic organoids from human pluripotent stem cells, mimicking early human organ development with remarkable fidelity.

🚨 Breakthrough in Solid Tumor CAR T Therapy! The first-ever RCT of CAR T-cell therapy in solid tumors shows promise! 💥 🧬 Satri-cel (CT041), a CLDN18.2-specific CAR T-cell therapy, improved PFS in patients with advanced gastric or gastro-oesophageal junction cancer vs standard treatments.

I’m incredibly honored to be named one of the 2025 Trailblazers in Higher Education by City & State New York. Thank you for this meaningful recognition & for highlighting the importance of innovation, education, & purpose-driven science.

🎥 MedNews Week x OncLive x Women in Lymphoma Present: 🌟 Voices in Lymphoma: Women Shaping Care 🌟 🔥 New Episode – June 17! 🔥 Dive into a must-watch conversation on evolving paradigms in first relapse DLBCL with two powerhouse leaders in lymphoma care: 👩‍⚕️ Dr. Sonali Smith 👩‍⚕️ Dr. Manali Kamdar

🔬 New findings from Dr. Marcela Maus & team at Mass General Hospital reveal a surprising twist in #CARTcell therapy: 🧬 While IFN-γ is often seen as a key player in immunotherapy, this study shows it may actually induce apoptosis in CD28-based CAR T cells, limiting their persistence and efficacy.

🧬 Loss of Y Chromosome (LOY): A Hidden Driver of Cancer Mortality in Men? New pan-cancer analysis reveals a critical link between LOY in immune cells and cancer outcomes:

📢 Interim Phase 2 COURAGE Trial Results (Regeneron): New data shows that ~35% of semaglutide-induced weight loss is due to lean mass loss — a key concern for overall health and function.

It's the last day of @ascocancer.bsky.social #ASCO25 and the last day of #OntheClock ⏱️ with MedNews Week. In this clip, MinhTri Nguyen, MD, of @stanfordhealthcare.bsky.social, discusses the SERENA6 data with @yleyfman.bsky.social Did he beat the clock? 👀

Next up #OntheClock ⏱️ with @yleyfman.bsky.social from MedNews Week at @ascocancer.bsky.social #ASCO25 is Arturo LoAIza-Bonilla MD, of @stlukeshealth.bsky.social, who provides an overview of his poster focused on transforming oncology clinical trial matching through multi-agent AI.

Live from the @ascocancer.bsky.social #ASCO25 conference floor, we have Liz O'Riordan, MD, of Royal Marsden Hospital, going #OntheClock ⏱️ with @yleyfman.bsky.social of MedNews Week. Check back for the full interview later on onclive.com!

Next up #OntheClock ⏱️ with @yleyfman.bsky.social of MedNews Week at @ascocancer.bsky.social #ASCO25 is Dr Laila Agrawal of Norton Cancer Institute, who highlights a session focused on sexual concerns among cancer survivors. Did she beat the clock? 👀

Next up: Dr Debora Barton of Full-Life Technologies, goes #OntheClock ⏱️ with @yleyfman.bsky.social of MedNews Week to discuss exciting research in the realm of prostate cancer presented via poster at this year's @ascocancer.bsky.social Annual Meeting. #ASCO25

Performance Evaluation of an AI-powered System for Clinical Trial Eligibility Using mCODE Data Standards - Yan Leyfman @yleyfman.bsky.social @drbonillaonc.bsky.social @massive-bio.bsky.social oncodaily.com/blog/yan-ley... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI

Oncologist Near Me - Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology @yleyfman.bsky.social oncodaily.com/oncolibrary/... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #OncologistNearMe

✨ NEW at #ASCO25: #OnTheClock ⏱️ from MedNews Week x OncLive! Oncologists get 1 minute to spotlight the most practice-changing data of the day. 🎤 Want in? 📍Find @yleyfman.bsky.social & Dr Chandler Park on the floor. Up first? Dr Harpreet Singh of Precision for Med. Did she beat the clock? 👀

Next up: @patrickhwumd.bsky.social of @moffittnews.bsky.social went #OntheClock ⏱️ with @yleyfman.bsky.social of MedNews Week to discuss what he feels to be the most exciting developments coming out of this year's @ascocancer.bsky.social Annual Meeting. Did he beat the clock? 👀 #ASCO25 #oncology

Next up #OntheClock ⏱️ with @yleyfman.bsky.social of MedNews Week, was Elliot Woods, MD, PhD, of Massachusetts General Hospital What were the data that he was most excited about at this year's @ascocancer.bsky.social #ASCO25? And, did he beat the clock? 👀 #oncology #medtwitter

Tingting Zhang, PhD, of @hear2care.bsky.social, also went #OntheClock ⏱️ with @yleyfman.bsky.social of MedNews Week at this year's @ascocancer.bsky.social Annual Meeting. #ASCO25 Check out what she felt were the biggest data of the day. Spoiler: She beat the clock. ⚡

Yan Leyfman Highlighted Social Media Equity Challenges in Oncology at ASCO 2025 @ascocancer.bsky.social @yleyfman.bsky.social oncodaily.com/insight/asco... #ASCO2025 #Cancer #MedNewsWeek #OncoDaily #Oncology

Next up #OntheClock ⏱️ is Dr Michael Wang of @mdanderson.bsky.social who spoke with @yleyfman.bsky.social of MedNews Week about the STARGLO data with glofitamab plus gemcitabine/oxaliplatin in relapsed/refractory DLBCL at @ascocancer.bsky.social #ASCO25. Here's what he had to say 🗣️:

@lymphomadoc.bsky.social of @mdanderson.bsky.social , joins @yleyfman.bsky.social of MedNews Week #OntheClock ⏱️ to discuss what he is most excited about at @ascocancer.bsky.social #ASCO25. Spoiler: He not only beats the clock, but has 28 seconds to spare.

🤔. Interesting to see long term effects & efficacy of such an approach. www.wsj.com/health/welln...

GLP-1 receptor agonists—commonly used to treat diabetes and obesity—may modestly reduce the risk of developing certain cancers, including colon and rectal cancer.

JAMA Study on Cancer Risks from CT Scans - Yan Leyfman @yleyfman.bsky.social oncodaily.com/science/yan-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerRisks #CT #CTScans #JAMA

MedNews Week x OncLive Present: 🌟 Voices in Lymphoma: Women Shaping Care 🌟 Thursday, May 22 @ 6:30 PM ET

The FDA has approved the first blood test to help diagnose Alzheimer's disease and guide treatment decisions for patients 55+ showing early symptoms. apnews.com/article/alzh...

A new study projects that the 93 million CT scans performed in the U.S. in 2023 could result in ~103,000 future cancers🎗️. 🔹 Children face higher per-scan risk 🔹 Adults account for the majority due to higher scan volume

🧠 Neurodegenerative diseases (NDDs) are a complex group of conditions marked by progressive neuronal loss, affecting memory, cognition, movement, and sensory function. As cases rise, the need for effective therapies becomes more urgent.

🏌️‍♂️💧 Does living near a golf course increase the risk of Parkinson’s disease (PD)? 📍 A new case-control study found that individuals living within 1–3 miles of a golf course had a higher risk of PD, with the greatest odds observed within 1 mile. Risk decreased with distance.

Excited to Share Our Cover Article in ONCOLOGY: Insights on AI in Cancer Care - Yan Leyfman @yleyfman.bsky.social oncodaily.com/insight/yan-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #CancerCare